DK2134330T3 - Kominationer af 5-ht2a-inverse agonister og antagonister med antipsykotika - Google Patents
Kominationer af 5-ht2a-inverse agonister og antagonister med antipsykotikaInfo
- Publication number
- DK2134330T3 DK2134330T3 DK08744091T DK08744091T DK2134330T3 DK 2134330 T3 DK2134330 T3 DK 2134330T3 DK 08744091 T DK08744091 T DK 08744091T DK 08744091 T DK08744091 T DK 08744091T DK 2134330 T3 DK2134330 T3 DK 2134330T3
- Authority
- DK
- Denmark
- Prior art keywords
- ht2a
- antagonists
- substances
- combinations
- inverse agonists
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 238000003874 inverse correlation nuclear magnetic resonance spectroscopy Methods 0.000 title 1
- 239000000126 substance Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Computing Systems (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89573507P | 2007-03-19 | 2007-03-19 | |
US90892107P | 2007-03-29 | 2007-03-29 | |
US1277107P | 2007-12-10 | 2007-12-10 | |
US2609208P | 2008-02-04 | 2008-02-04 | |
PCT/US2008/057557 WO2008116024A2 (en) | 2007-03-19 | 2008-03-19 | Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2134330T3 true DK2134330T3 (da) | 2013-08-05 |
Family
ID=39744932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08744091T DK2134330T3 (da) | 2007-03-19 | 2008-03-19 | Kominationer af 5-ht2a-inverse agonister og antagonister med antipsykotika |
Country Status (11)
Country | Link |
---|---|
US (3) | US20090053329A1 (da) |
EP (1) | EP2134330B1 (da) |
JP (1) | JP2010522198A (da) |
CN (1) | CN101677971A (da) |
AU (1) | AU2008228833B9 (da) |
CA (1) | CA2681506C (da) |
DK (1) | DK2134330T3 (da) |
ES (1) | ES2423485T3 (da) |
HR (1) | HRP20130713T1 (da) |
PL (1) | PL2134330T3 (da) |
WO (1) | WO2008116024A2 (da) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2134330T3 (da) | 2007-03-19 | 2013-08-05 | Acadia Pharm Inc | Kominationer af 5-ht2a-inverse agonister og antagonister med antipsykotika |
PL2445502T5 (pl) | 2009-06-25 | 2023-03-13 | Alkermes Pharma Ireland Limited | Związki heterocykliczne do leczenia zaburzeń neurologicznych i psychologicznych |
JP5732453B2 (ja) * | 2009-06-25 | 2015-06-10 | アルカーメス ファーマ アイルランド リミテッド | Nh酸性化合物のプロドラッグ |
PT2506712T (pt) | 2009-12-04 | 2019-05-31 | Alkermes Pharma Ireland Ltd | Derivados de morfinano para o tratamento da overdose por fármaco |
US20110166156A1 (en) * | 2010-01-07 | 2011-07-07 | Alkermes, Inc. | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease |
US20110166128A1 (en) * | 2010-01-07 | 2011-07-07 | Alkermes, Inc. | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders |
ES2647361T3 (es) * | 2010-01-07 | 2017-12-21 | Alkermes Pharma Ireland Limited | Profármacos de sales de amonio cuaternario |
ES2574210T3 (es) * | 2010-03-02 | 2016-06-15 | Fervent Pharmaceuticals, Llc | Métodos y composiciones para tratar o prevenir los síntomas de las variaciones hormonales |
US20130123285A1 (en) * | 2010-05-14 | 2013-05-16 | University Of Rochester | Compositions and Methods for Targeting A3G:RNA Complexes |
CA2802733C (en) | 2010-06-24 | 2017-11-21 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
LT2608670T (lt) | 2010-08-23 | 2019-01-25 | Alkermes Pharma Ireland Limited | Antipsichotikų sukelto padidėjusio svorio sumažinimo būdai |
US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
CN103561746B (zh) | 2011-03-18 | 2018-05-29 | 奥克梅斯制药爱尔兰有限公司 | 包含脱水山梨糖醇酯的药物组合物 |
US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
WO2013088255A1 (en) | 2011-12-15 | 2013-06-20 | Alkermes Pharma Ireland Limited | Prodrugs of secondary amine compounds |
US8822488B2 (en) | 2011-12-15 | 2014-09-02 | Alkermes Pharma Ireland Limited | Compositions of buprenorphine and μ antagonists |
US9999670B2 (en) | 2012-03-19 | 2018-06-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
ES2764383T3 (es) | 2012-03-19 | 2020-06-03 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden ésteres de glicerol |
EP2827868B8 (en) | 2012-03-19 | 2019-12-18 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
CN102657868A (zh) * | 2012-05-30 | 2012-09-12 | 中国药科大学 | 5-羟色胺2受体拮抗剂或转运体抑制剂治疗脂肪肝或高脂血症 |
NZ748572A (en) | 2012-09-19 | 2020-07-31 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions having improved storage stability |
CA2887893C (en) | 2012-10-09 | 2021-07-06 | Douglas SEARS | Therapeutic treatment for attention deficit disorder |
US9446037B2 (en) | 2012-11-27 | 2016-09-20 | Acadia Pharmaceuticals Inc. | Methods for the treatment of parkinson's disease psychosis using pimavanserin |
WO2014190271A2 (en) | 2013-05-24 | 2014-11-27 | Alkermes Pharma Ireland Limted | Methods for treating depressive symptoms |
CA2911231C (en) | 2013-05-24 | 2021-12-07 | Alkermes Pharma Ireland Limited | Morphan and morphinan analogues, and methods of use |
CA2943213C (en) | 2014-03-20 | 2022-07-05 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
PT3325444T (pt) | 2015-07-20 | 2021-09-22 | Acadia Pharm Inc | Métodos para preparar n-(4-fluorobenzil)-n-(1-metilpiperidina-4-il)-n'-(4-(2-metilpropiloxi)fenilmetil)carbamida e o seu sal de tartarato e forma polimórfica c |
US20170119704A1 (en) * | 2015-10-13 | 2017-05-04 | Ovid Therapeutics Inc. | Treatment of cognitive impairment |
CN105929030B (zh) * | 2015-12-18 | 2018-08-21 | 重庆两江药物研发中心有限公司 | 一种哌马色林中有机杂质的检测方法 |
WO2017156429A1 (en) * | 2016-03-10 | 2017-09-14 | The Regents Of The University Of Michigan | Methods of treating neurodegenerative diseases |
US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
WO2018118626A1 (en) | 2016-12-20 | 2018-06-28 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
US11135211B2 (en) | 2017-04-28 | 2021-10-05 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
US20210077479A1 (en) | 2017-08-30 | 2021-03-18 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
WO2019081764A1 (en) | 2017-10-26 | 2019-05-02 | Consejo Superior De Investigaciones Científicas (Csic) | ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS |
KR102036909B1 (ko) * | 2017-11-28 | 2019-10-25 | 한국과학기술원 | 신규 디스토니아 치료용 약학적 조성물 |
CA3088356A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
MX2020005518A (es) | 2017-12-05 | 2020-11-06 | Sunovion Pharmaceuticals Inc | Mezclas no racemicas y usos de las mismas. |
CA3092335A1 (en) | 2018-03-05 | 2019-09-12 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
WO2020092618A1 (en) * | 2018-10-30 | 2020-05-07 | Acadia Pharmaceuticals Inc. | Methods of treating depression, anxiety and sexual dysfunction using the compound primavanserin |
AU2020211938A1 (en) * | 2019-01-22 | 2021-07-29 | Indivior Uk Limited | Methods for treating schizophrenia |
AU2020286441A1 (en) | 2019-06-04 | 2022-01-06 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
WO2021016369A1 (en) * | 2019-07-22 | 2021-01-28 | Acadia Pharmaceuticals Inc. | Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder |
MX2022001751A (es) * | 2019-08-13 | 2022-06-02 | Univ Maryland | Metodos de tratamiento de trastornos psicologicos y cerebrales. |
CN111297805A (zh) * | 2019-12-19 | 2020-06-19 | 赵洁 | 一种匹莫范色林的脂质体及其制备工艺 |
CA3168926A1 (en) * | 2020-02-28 | 2021-09-02 | Matthias Emanuel LIECHTI | Ketanserin for reducing acute effects of psychedelic drugs |
WO2021214950A1 (ja) * | 2020-04-23 | 2021-10-28 | 国立大学法人島根大学 | 精神疾患を治療、予防又は管理するための医薬組成物 |
BR112022022331A2 (pt) * | 2020-05-05 | 2022-12-20 | Univ Basel | Método para melhorar efeitos terapêuticos positivos de um psicodélico, composição, e método para tratar um paciente |
US20230346811A1 (en) * | 2020-09-18 | 2023-11-02 | Mydecine Innovations Group Inc. | Novel Formulations of Psilocybin And Psilocin Compounds as Serotonin Agonists in Combination With 3,4 Methylenedioxymethamphetamine (MDMA) |
WO2022094230A1 (en) * | 2020-11-02 | 2022-05-05 | Acadia Pharmaceuticals Inc. | Compounds for treating psychosis or depression |
EP4243768A1 (en) | 2020-11-12 | 2023-09-20 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
WO2022265878A1 (en) * | 2021-06-14 | 2022-12-22 | Mind Medicine, Inc. | Controlling effects after 5ht2a agonists administration |
AU2022309017A1 (en) | 2021-07-07 | 2024-01-25 | Terran Biosciences Inc. | N,n-dimethyltryptamine and related psychedlics and uses thereof |
CA3237988A1 (en) | 2021-11-12 | 2023-05-19 | Terran Biosciences Inc. | Psilocybin and o-acetylpsilocin, salts and solid state forms thereof |
CN114712365B (zh) * | 2022-06-07 | 2022-08-23 | 山东绿叶制药有限公司 | Trk抑制剂在制备治疗迟发性运动障碍药物中的应用 |
CN115919860B (zh) * | 2022-12-05 | 2023-11-10 | 中国药科大学 | 氟班色林在制备治疗雄激素脱发药物中的用途 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE794333A (fr) | 1972-01-20 | 1973-07-19 | Wyeth John & Brother Ltd | Composes heterocycliques azotes therapeutiques |
GB1507462A (en) | 1974-03-21 | 1978-04-12 | Gallardo Antonio Sa | N-heterocyclic substituted benzamides methods for their preparation and compositions containing them |
US3983234A (en) | 1974-07-04 | 1976-09-28 | Sandoz Ltd. | Treatment of dyskinesias |
JPS5152176A (da) | 1974-10-12 | 1976-05-08 | Yoshitomi Pharmaceutical | |
GB1586468A (en) | 1976-10-29 | 1981-03-18 | Anphar Sa | Piperidine derivatives |
CA1140119A (en) | 1978-04-03 | 1983-01-25 | Joseph Torremans | N-heterocyclyl-4-piperidinamines |
US4255432A (en) | 1979-09-06 | 1981-03-10 | Syntex (U.S.A.) Inc. | 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof |
US4332804A (en) | 1981-03-23 | 1982-06-01 | Syntex (U.S.A.) Inc. | 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones |
US4353901A (en) | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones |
US4353900A (en) | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
GB8527052D0 (en) | 1985-11-02 | 1985-12-04 | Beecham Group Plc | Compounds |
GB8621892D0 (en) | 1986-09-11 | 1986-10-15 | Lundbeck & Co As H | Organic compound |
FR2642069B1 (fr) | 1989-01-20 | 1991-04-12 | Rhone Poulenc Sante | Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent |
US5214055A (en) | 1990-05-18 | 1993-05-25 | Adir Et Compagnie | Aminopiperidine 4-oxo-4H-chromen-2-yl compounds |
US5216165A (en) | 1990-10-03 | 1993-06-01 | American Home Products Corporation | N-substituted aminoquinolines as analgesic agents |
IT1252227B (it) | 1991-12-17 | 1995-06-05 | Ciba Geigy Spa | Composti tetrametilpiperidinici atti all'impiego come stabilizzanti per materiali organici |
JPH05208517A (ja) | 1992-01-31 | 1993-08-20 | Nec Corp | 印字制御回路 |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
CA2123728A1 (en) | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Urea derivatives and their use as acat inhibitors |
EP0700385A1 (en) | 1993-05-26 | 1996-03-13 | Smithkline Beecham Laboratoires Pharmaceutiques | Novel compounds |
US5707798A (en) | 1993-07-13 | 1998-01-13 | Novo Nordisk A/S | Identification of ligands by selective amplification of cells transfected with receptors |
DE4404183A1 (de) | 1994-02-10 | 1995-08-17 | Merck Patent Gmbh | 4-Amino-1-piperidylbenzoylguanidine |
US5795894A (en) | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
BR9610277A (pt) | 1995-08-31 | 1999-07-06 | Schering Corp | Derivados de piperazino como antagonistas de neurowuinina |
CA2233204A1 (en) | 1995-09-29 | 1997-04-03 | Joseph A. Jakubowski | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
ATE320804T1 (de) | 1995-12-07 | 2006-04-15 | Daniel C Javitt | Behandlung negativer und kognitiver symptome der schizophrenie mit antagonisten der glycinaufnahme |
WO1997038665A2 (en) | 1996-04-03 | 1997-10-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
AU2733997A (en) | 1996-04-17 | 1997-11-07 | Du Pont Pharmaceuticals Company | N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors |
US5869488A (en) | 1996-05-01 | 1999-02-09 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
US5877173A (en) | 1996-08-28 | 1999-03-02 | Washington University | Preventing neuronal degeneration in Alzheimer's disease |
ATE266673T1 (de) | 1996-09-10 | 2004-05-15 | Boehringer Ingelheim Pharma | Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DE19643331A1 (de) | 1996-10-21 | 1998-04-23 | Thomae Gmbh Dr K | 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6057338A (en) | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
KR20010012316A (ko) | 1997-05-08 | 2001-02-15 | 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 | 프로테아제 억제제 |
GB9718833D0 (en) | 1997-09-04 | 1997-11-12 | Merck Sharp & Dohme | Therapeutic agents |
AU764766B2 (en) | 1998-04-14 | 2003-08-28 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
US6140509A (en) | 1998-06-26 | 2000-10-31 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
GB9816263D0 (en) | 1998-07-24 | 1998-09-23 | Merck Sharp & Dohme | Therapeutic agents |
US6358698B1 (en) | 1998-10-07 | 2002-03-19 | Acadia Pharmacueticals Inc. | Methods of identifying inverse agonists of the serotonin 2A receptor |
WO2000023076A1 (en) | 1998-10-16 | 2000-04-27 | Suntory Limited | Aminophenoxyacetic acid derivatives as neuroprotectants |
US6150393A (en) | 1998-12-18 | 2000-11-21 | Arena Pharmaceuticals, Inc. | Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors |
EP1013276A1 (en) | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
WO2000056335A1 (en) | 1999-03-24 | 2000-09-28 | The Regents Of The University Of California | Methods for treating neurodegenerative disorders using aspartyl protease inhibitors |
US6399619B1 (en) | 1999-04-06 | 2002-06-04 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
HUP0201033A3 (en) | 1999-05-17 | 2003-03-28 | Novo Nordisk As | Glucagon antagonists/inverse agonists, process for their preparation and their use |
US20050148018A1 (en) | 1999-10-07 | 2005-07-07 | David Weiner | Methods of identifying inverse agonists of the serotonin 2A receptor |
FR2802206B1 (fr) | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
US7022698B2 (en) | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
CN101230034A (zh) | 2000-03-06 | 2008-07-30 | 阿卡蒂亚药品公司 | 用于治疗5-羟色胺相关性疾病的氮杂环化合物 |
GB0011838D0 (en) | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
DE60141752D1 (de) | 2000-06-30 | 2010-05-20 | Innogenetics Nv | Differentielle diagnose von neurologischen krankheiten |
KR20030029978A (ko) | 2000-09-25 | 2003-04-16 | 액테리온 파마슈티칼 리미티드 | 말라리아에 유용한 치환된 아미노-아자-사이클로알칸 |
WO2002076464A1 (en) | 2001-03-22 | 2002-10-03 | Arena Pharmaceuticals, Inc. | Anti-psychosis combination |
GB0108099D0 (en) | 2001-03-30 | 2001-05-23 | Hoffmann La Roche | Aminopiperidine derivatives |
NZ571695A (en) | 2001-12-28 | 2010-02-26 | Acadia Pharm Inc | Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events |
WO2003062206A2 (en) | 2002-01-23 | 2003-07-31 | Arena Pharmaceuticals, Inc. | Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
UY27668A1 (es) | 2002-02-20 | 2003-10-31 | Pfizer Prod Inc | Composición de ziprasidona y controles sintéticos |
GB0208279D0 (en) | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
JP2005533813A (ja) | 2002-06-24 | 2005-11-10 | アカディア ファーマシューティカルズ,インコーポレーテッド | セロトニン受容体作用物質としてのn−置換ピペリジン誘導体 |
AU2003284899A1 (en) | 2002-10-29 | 2004-05-25 | Miicro, Inc. | Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake |
US7601740B2 (en) | 2003-01-16 | 2009-10-13 | Acadia Pharmaceuticals, Inc. | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
US20040224942A1 (en) | 2003-01-23 | 2004-11-11 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
EP2272514A1 (en) | 2003-12-02 | 2011-01-12 | PharmaNeuroBoost N.V. | Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases |
PT1696931E (pt) | 2003-12-22 | 2009-06-12 | Acadia Pharm Inc | Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas |
US7820695B2 (en) * | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
US20050261278A1 (en) * | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
DK1794126T3 (da) | 2004-09-27 | 2013-06-24 | Acadia Pharm Inc | Krystallinsk form af N-(-4-fluorbenzyl)-N-(1-methylpiperidn-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamid-hemitartrat |
JP5208517B2 (ja) | 2005-01-10 | 2013-06-12 | タヘリ ラドュカ エルエルシー | 血管移植物およびその製造方法 |
WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
AU2006229904A1 (en) | 2005-03-30 | 2006-10-05 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
WO2007133802A2 (en) * | 2006-05-15 | 2007-11-22 | Acadia Pharmaceuticals Inc. | Pharmaceutical formulations of pimavanserin |
DK2134330T3 (da) | 2007-03-19 | 2013-08-05 | Acadia Pharm Inc | Kominationer af 5-ht2a-inverse agonister og antagonister med antipsykotika |
-
2008
- 2008-03-19 DK DK08744091T patent/DK2134330T3/da active
- 2008-03-19 ES ES08744091T patent/ES2423485T3/es active Active
- 2008-03-19 CN CN200880016491A patent/CN101677971A/zh active Pending
- 2008-03-19 EP EP20080744091 patent/EP2134330B1/en active Active
- 2008-03-19 WO PCT/US2008/057557 patent/WO2008116024A2/en active Application Filing
- 2008-03-19 US US12/051,807 patent/US20090053329A1/en not_active Abandoned
- 2008-03-19 CA CA2681506A patent/CA2681506C/en active Active
- 2008-03-19 AU AU2008228833A patent/AU2008228833B9/en active Active
- 2008-03-19 JP JP2009554722A patent/JP2010522198A/ja active Pending
- 2008-03-19 PL PL08744091T patent/PL2134330T3/pl unknown
-
2013
- 2013-01-30 US US13/754,769 patent/US9050343B2/en active Active
- 2013-07-29 HR HRP20130713AT patent/HRP20130713T1/hr unknown
-
2015
- 2015-05-01 US US14/702,313 patent/US20150231126A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HRP20130713T1 (en) | 2013-09-30 |
US20130143901A1 (en) | 2013-06-06 |
ES2423485T3 (es) | 2013-09-20 |
CA2681506C (en) | 2016-05-24 |
PL2134330T3 (pl) | 2013-10-31 |
AU2008228833A1 (en) | 2008-09-25 |
EP2134330A2 (en) | 2009-12-23 |
CN101677971A (zh) | 2010-03-24 |
AU2008228833B9 (en) | 2013-10-24 |
US20090053329A1 (en) | 2009-02-26 |
AU2008228833B2 (en) | 2013-10-10 |
JP2010522198A (ja) | 2010-07-01 |
WO2008116024A3 (en) | 2008-12-31 |
US9050343B2 (en) | 2015-06-09 |
EP2134330B1 (en) | 2013-05-08 |
WO2008116024A2 (en) | 2008-09-25 |
US20150231126A1 (en) | 2015-08-20 |
CA2681506A1 (en) | 2008-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2134330T3 (da) | Kominationer af 5-ht2a-inverse agonister og antagonister med antipsykotika | |
DK2570467T3 (da) | Sammensætninger af tetrafluorpropen og carbonhydrider | |
DK2015754T3 (da) | Anvendelse af dpp-iv-inhibitorer | |
DK2211901T3 (da) | Vaccination med multiple clader af h5-influenza-a-virus | |
BRPI0818003A2 (pt) | inibidores de csf-1r, composições e métodos de uso | |
DK2117542T3 (da) | Kombinationer af beta-2-adrenoceptor-agonistisk benzothiazolon | |
CR10815A (es) | Nuevos derivados de isoquinolina e isoquinolinona sustituidos | |
BRPI0810497A2 (pt) | Refrigerador e dispositivo elétrico | |
DK2142529T3 (da) | Trpv1-antagonister og anvendelser deraf | |
DK2118140T3 (da) | Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf | |
DK2513193T3 (da) | Forbedrede blends af polyarylenethere og polyarylensulfider | |
BRPI0819573A2 (pt) | Composição e artigo | |
BRPI1015315A2 (pt) | composto heterocíclico fundido e uso dos mesmos | |
DK2257618T3 (da) | Fremstilling af glykosylerede polypeptider i mikroalger | |
DK3255146T3 (da) | Præparater og fremgangsmåder omfattende histidyl-tRNA-synthetasesplejsningsvarianter med ikke-kanoniske biologiske aktiviteter | |
DK2046740T3 (da) | Forbindelser med CRTH2-antagonistisk virkning | |
DK2106423T3 (da) | Bituminøs sammensætning med termoreversible egenskaber | |
DK2318396T3 (da) | Krystalform af posaconazol | |
DK2352756T3 (da) | Højaffin T-cellereceptor og anvendelse af denne | |
DK2231614T3 (da) | Quinolinderivativer og anvendelse af disse som fungicider | |
CR20130360A (es) | Compuesto heterocíclico y su uso | |
FI20075600A0 (fi) | Komponentin eliniän määritys | |
DK2254598T3 (da) | Kombination af alfa 7-nikotinagonister og antipsykotika | |
DK2170827T3 (da) | Indolin-2-oner og aza-indolin-2-oner | |
DK2111555T3 (da) | Diagnosticering af præeklampsi |